La sitagliptine dans le traitement du diabete de type 2: le point, cinq ans apres sa commercialisation. ; Sitagliptin in the treatment of type 2 diabetes: insights five years after commercialisation
peer reviewed ; Sitagliptin (Januvia) was the first selective inhibitor of dipeptidyl peptidase-4 commercialized for the management of type 2 diabetes. It is also available as a fixed-dose combination with meformin (Janumet). Almost 5 years after its launch in Belgium, the present review summarizes the most recent data regarding the clinical efficacy of this antidiabetic agent, the controversy about its safety profile, its use at lower dosage in case of moderate to severe renal insufficiency, the various indications that have been successively accepted and reimbursed, and, finally, the perspec... Mehr ...
peer reviewed ; Sitagliptin (Januvia) was the first selective inhibitor of dipeptidyl peptidase-4 commercialized for the management of type 2 diabetes. It is also available as a fixed-dose combination with meformin (Janumet). Almost 5 years after its launch in Belgium, the present review summarizes the most recent data regarding the clinical efficacy of this antidiabetic agent, the controversy about its safety profile, its use at lower dosage in case of moderate to severe renal insufficiency, the various indications that have been successively accepted and reimbursed, and, finally, the perspectives offered by a large ongoing cardiovascular outcome trial (TECOS). ; Résumé : La sitagliptine (Januvia®) a été le premier inhibiteur sélectif de la dipeptidyl peptidase-4 commercialisé pour le traitement du diabète de type 2. Elle est également disponible en combinaison fixe avec la metformine (Janumet®). Quelque 5 années après sa commercialisation en Belgique, cette revue fait le point sur les dernières données disponibles concernant l’efficacité clinique de cet antidiabétique oral, la controverse à propos de son profil de sécurité, son utilisation à dose réduite en présence d’une insuffisance rénale modérée à sévère, les différentes indications successivement reconnues et remboursées, et, enfin, les perspectives offertes par la grande étude de prévention cardio-vasculaire actuellement en cours (TECOS). Mots-clés : Diabète de type 2 - Incrétine - Inhibiteur de la dipeptidyl peptidase-4 - Insuffisance rénale - Metformine - Sitagliptine